Martin LaFleur
@martinlafleur.bsky.social
Postdoctoral Fellow studying tumor immunology in the Boston area (Arlene Sharpe’s lab). In my free time, I enjoy reading and traveling with my wife Sarah.
Graphical abstract of our recent work in
@natimmunol.nature.com. STUB1 regulates tumor immunity through targeting cytokine receptors using an as yet unknown selectivity mechanism. We have likened STUB1 to a puppet master, controlling the cytokines T cells can sense.
www.nature.com/articles/s41...
@natimmunol.nature.com. STUB1 regulates tumor immunity through targeting cytokine receptors using an as yet unknown selectivity mechanism. We have likened STUB1 to a puppet master, controlling the cytokines T cells can sense.
www.nature.com/articles/s41...
September 2, 2025 at 2:28 PM
Graphical abstract of our recent work in
@natimmunol.nature.com. STUB1 regulates tumor immunity through targeting cytokine receptors using an as yet unknown selectivity mechanism. We have likened STUB1 to a puppet master, controlling the cytokines T cells can sense.
www.nature.com/articles/s41...
@natimmunol.nature.com. STUB1 regulates tumor immunity through targeting cytokine receptors using an as yet unknown selectivity mechanism. We have likened STUB1 to a puppet master, controlling the cytokines T cells can sense.
www.nature.com/articles/s41...
Excited to share our paper in
@natimmunol.nature.com! Using in vivo #CRISPR screens we identify the E3 ligase STUB1 as a new cancer immunotherapy target in CD8 T cells. STUB1 is a dual function target: STUB1 KO promotes CD8 responses and STUB1 KO hinders tumor cells. www.nature.com/articles/s41...
@natimmunol.nature.com! Using in vivo #CRISPR screens we identify the E3 ligase STUB1 as a new cancer immunotherapy target in CD8 T cells. STUB1 is a dual function target: STUB1 KO promotes CD8 responses and STUB1 KO hinders tumor cells. www.nature.com/articles/s41...
A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity
Nature Immunology - LaFleur, Milling et al. perform an in vivo CRISPR screen of CD8+ T cells responding to tumors. They identify the E3 ubiquitin ligase STUB1 as a potent negative regulator of CD8+...
rdcu.be
August 12, 2025 at 6:49 PM
Excited to share our paper in
@natimmunol.nature.com! Using in vivo #CRISPR screens we identify the E3 ligase STUB1 as a new cancer immunotherapy target in CD8 T cells. STUB1 is a dual function target: STUB1 KO promotes CD8 responses and STUB1 KO hinders tumor cells. www.nature.com/articles/s41...
@natimmunol.nature.com! Using in vivo #CRISPR screens we identify the E3 ligase STUB1 as a new cancer immunotherapy target in CD8 T cells. STUB1 is a dual function target: STUB1 KO promotes CD8 responses and STUB1 KO hinders tumor cells. www.nature.com/articles/s41...